Loading...
XNYSEVH
Market cap1.46bUSD
Jan 10, Last price  
12.54USD
1D
-0.48%
1Q
-53.66%
Jan 2017
-15.27%
IPO
-34.24%
Name

Evolent Health Inc

Chart & Performance

D1W1MN
XNYS:EVH chart
P/E
—
P/S
0.74
EPS
—
Div Yield, %
1.29%
Shrs. gr., 5y
7.54%
Rev. gr., 5y
25.65%
Revenues
1.96b
+45.26%
8,346,00025,671,000096,878,000254,188,000434,950,000627,063,000846,383,0001,022,433,000907,957,0001,352,013,0001,963,896,000
Net income
-113m
L+504.46%
-19,263,00020,023,000-25,246,000332,494,000-159,742,000-60,665,000-52,658,000-305,580,000-334,246,000-30,284,000-18,701,000-113,040,000
CFO
143m
P
-12,767,000-13,629,000-75,094,000-19,829,000-35,510,000-27,958,000-20,651,000-42,645,000-16,225,00038,747,000-11,553,000142,582,000
Earnings
Feb 20, 2025

Profile

Evolent Health, Inc., a healthcare company, through its subsidiary, Evolent Health LLC, provides clinical and administrative solutions to payers and providers in the United States. It operates in two segments, Evolent Health Services and Clinical Solutions. The Evolent Health Services segment provides an integrated administrative and clinical platform for health plan administration and population health management. It offers financial and administrative management services, such as health plan services, risk management, analytics and reporting, and leadership and management; and Identifi, a proprietary technology system that aggregates and analyzes data, manages care workflows, and engages patients, population health performance that delivers patient-centric cost-effective care. The Clinical Solutions segment offers specialty care management services support a range of specialty care delivery stakeholders during their transition from fee-for-service to value-based care, independent of their stage of maturation and specific market dynamics in oncology and cardiology; and holistic total cost of care improvement. The company was founded in 2011 and is headquartered in Arlington, Virginia.
URL
https://www.evolenthealth.com/
IPO date
Jun 05, 2015
Employees
5,100
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
1,963,896
45.26%
1,352,013
48.91%
Cost of revenue
1,503,426
1,062,429
Unusual Expense (Income)
NOPBT
460,470
289,584
NOPBT Margin
23.45%
21.42%
Operating Taxes
(89,365)
(43,376)
Tax Rate
NOPAT
549,835
332,960
Net income
(113,040)
504.46%
(18,701)
-38.25%
Dividends
(18,793)
(14,884)
Dividend yield
0.51%
0.57%
Proceeds from repurchase of equity
(13,866)
BB yield
0.53%
Debt
Debt current
19,476
7,122
Long-term debt
682,805
532,128
Deferred revenue
2,533
Other long-term liabilities
289,996
48,161
Net debt
504,561
346,575
Cash flow
Cash from operating activities
142,582
(11,553)
CAPEX
(28,745)
(38,361)
Cash from investing activities
(415,544)
(259,115)
Cash from financing activities
281,340
131,541
FCF
596,559
327,627
Balance
Cash
192,825
188,200
Long term investments
4,895
4,475
Excess cash
99,525
125,074
Stockholders' equity
(719,297)
(606,317)
Invested Capital
2,731,528
1,992,546
ROIC
23.28%
18.51%
ROCE
22.73%
20.82%
EV
Common stock shares outstanding
111,251
93,699
Price
33.03
17.63%
28.08
1.48%
Market cap
3,674,621
39.66%
2,631,068
10.48%
EV
4,179,182
2,977,643
EBITDA
583,885
356,779
EV/EBITDA
7.16
8.35
Interest
54,205
15,572
Interest/NOPBT
11.77%
5.38%